Banco de Sabadell S.A Has $1.41 Million Position in Novo Nordisk A/S (NYSE:NVO)

Banco de Sabadell S.A grew its holdings in Novo Nordisk A/S (NYSE:NVOGet Rating) by 10.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,593 shares of the company’s stock after purchasing an additional 1,156 shares during the quarter. Banco de Sabadell S.A’s holdings in Novo Nordisk A/S were worth $1,410,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Ahrens Investment Partners LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. Bell Investment Advisors Inc bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $28,000. Fortis Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $29,000. Clearstead Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 109.3% in the third quarter. Clearstead Advisors LLC now owns 314 shares of the company’s stock valued at $30,000 after buying an additional 164 shares during the period. Finally, Allegheny Financial Group LTD bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $34,000.

NYSE:NVO opened at $107.74 on Friday. Novo Nordisk A/S has a 1 year low of $78.71 and a 1 year high of $122.16. The firm has a 50 day moving average of $111.23 and a 200-day moving average of $107.38. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $253.71 billion, a P/E ratio of 32.07, a price-to-earnings-growth ratio of 2.10 and a beta of 0.47.

Novo Nordisk A/S (NYSE:NVOGet Rating) last posted its earnings results on Friday, April 29th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.09. Novo Nordisk A/S had a net margin of 33.16% and a return on equity of 72.67%. The company had revenue of $6.34 billion during the quarter, compared to analysts’ expectations of $5.82 billion. As a group, analysts forecast that Novo Nordisk A/S will post 3.44 EPS for the current fiscal year.

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 5th. Stockholders of record on Monday, March 28th were paid a $0.741 dividend. The ex-dividend date was Friday, March 25th. This represents a dividend yield of 1.1%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. Novo Nordisk A/S’s payout ratio is 44.05%.

Several equities research analysts recently weighed in on the stock. Citigroup upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, March 2nd. Barclays increased their target price on shares of Novo Nordisk A/S from 850.00 to 875.00 and gave the company an “overweight” rating in a research note on Thursday, May 12th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $104.00 target price for the company in a research note on Friday, February 25th. StockNews.com assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Finally, Berenberg Bank raised their price target on shares of Novo Nordisk A/S from 585.00 to 780.00 and gave the stock a “hold” rating in a research note on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $563.50.

Novo Nordisk A/S Company Profile (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Featured Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.